The Generalized Anxiety Disorder (GAD) drugs in development market research report provides comprehensive information on the therapeutics under development for Generalized Anxiety Disorder (GAD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Generalized Anxiety Disorder (GAD). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Generalized Anxiety Disorder (GAD) and features dormant and discontinued products.
GlobalData tracks 31 drugs in development for Generalized Anxiety Disorder (GAD) by 29 companies/universities/institutes. The top development phase for Generalized Anxiety Disorder (GAD) is phase ii with nine drugs in that stage. The Generalized Anxiety Disorder (GAD) pipeline has 31 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Generalized Anxiety Disorder (GAD) pipeline products market are: INVENT Pharmaceuticals, Cybin and Diamond Therapeutics.
The key targets in the Generalized Anxiety Disorder (GAD) pipeline products market include 5-Hydroxytryptamine Receptor 2A, Gamma Aminobutyric Acid Type A Receptor Subunit, and 5-Hydroxytryptamine Receptor 1A.
The key mechanisms of action in the Generalized Anxiety Disorder (GAD) pipeline product include 5-Hydroxytryptamine Receptor 2A Agonist with five drugs in Phase II. The Generalized Anxiety Disorder (GAD) pipeline products include seven routes of administration with the top ROA being Oral and three key molecule types in the Generalized Anxiety Disorder (GAD) pipeline products market including Small Molecule, and Biologic.
Generalized Anxiety Disorder (GAD) overview
Generalized anxiety disorder is a mental health disorder that produces fear, worry, and a constant feeling of being overwhelmed. It is characterized by excessive, persistent, and unrealistic worry about everyday things. Individuals with GAD typically experience heightened anxiety and apprehension, anticipating negative outcomes in everyday situations. Physical symptoms may include restlessness, muscle tension, fatigue, and difficulty concentrating. Unlike specific phobias or panic disorders, GAD is not limited to particular triggers and can encompass a broad range of concerns. The persistent nature of the anxiety can significantly impact daily functioning and overall well-being. Treatment often involves a combination of therapy, such as cognitive-behavioral therapy (CBT), and medication to manage symptoms and improve quality of life.
For a complete picture of Generalized Anxiety Disorder (GAD)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
